Stryker touts reduced post-stroke disability, improved functionality in Trevo anti-stroke trial
Stryker (NYSE:SYK) yesterday released results from the Dawn trial of its Trevo stent retriever anti-stroke device in treating patients suffering from ischemic stroke, touting decreased post-stroke disability and improved functional independence at 90 days.
The Dawn trial from the Kalamazoo, Mich.-based company compared the use of Trevo thrombectomy device combined with anticoagulant drugs with the drugs alone between 6 and 24 hours after the patient was last known to be well.
“Stryker continues to push clinical advancement in the field of stroke. We’re excited about the results released today, offering the first level-one evidence that late and unwitnessed stroke patients who receive mechanical thrombectomy may have better outcomes. Today, only a very small portion of the patient population is treated with a stent retriever. Data from this trial may result in changes to patient selection, allowing more stroke patients to receive endovascular treatment,” neurovascular division prez Mark Paul said in a prepared statement.
Results from 206 patients in the trial indicated a 48.6% rate of decreased post-stroke disability and improved functional independence at 90 days for patients treated with the Trevo and anticoagulants, versus 13.1% for those treated with medication alone.
Data also indicated that 1 in 2.8 patients treated with the Trevo device within 24 hours were saved from severe disability, which the company said “appears to be as beneficial and imperative as in patients treated in the perviously studied less-than-6-hour time window.”
“Despite the longer times to treatment, the reduction in disability in this trial was highly significant – possibly representing the largest treatment effect ever seen in an endovascular stroke trial. These results offer hope for thousands of stroke patients worldwide who arrive at the hospital outside the six hour treatment window,” co-principal investigator Dr. Raul Nogueira of the Grady Memorial Hospital/Emory University said in prepared remarks.
“This is great news for patients who present in the late time window who may still benefit from this treatment. The number needed to treat was only 2.8, indicating we may see a 270% increase in patients who are able to live an independent lifestyle free of severe disability,” co-principal investigator Dr. Tudor Jovin of the University of Pittsburgh Medical Center said in a press release.